| 0 (0%) | 01-21 05:33 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 106.14 | 1-year : | 123.98 |
| Resists | First : | 90.87 | Second : | 106.14 |
| Pivot price | 90.67  |
|||
| Supports | First : | 89.53 | Second : | 88.7 |
| MAs | MA(5) : | 90.84 |
MA(20) : | 90.62 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 99 |
D(3) : | 98.9  |
| RSI | RSI(14): 68.8 |
|||
| 52-week | High : | 90.87 | Low : | 88.7 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ATTR ] has closed below upper band by 18.6%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 90.93 - 91.36 | 91.36 - 91.77 |
| Low: | 89.71 - 90.23 | 90.23 - 90.7 |
| Close: | 90.04 - 90.83 | 90.83 - 91.57 |
Tue, 20 Jan 2026
Nerve Damage and Transthyretin Cardiac Amyloidosis (ATTR-CM) - Everyday Health
Tue, 20 Jan 2026
Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy: A Marker of Disease Severity but Not an Independent Predictor of Mortality - Cureus
Mon, 19 Jan 2026
Future Directions in ATTR-CM - HCP Live
Thu, 15 Jan 2026
AF in ATTR-CA: Prevalence, Predictors and Protective Factors - American College of Cardiology
Thu, 04 Dec 2025
4 Factors That Affect Your Transthyretin Amyloidosis (ATTR) Prognosis - Health: Trusted and Empathetic Health and Wellness Information
Tue, 02 Dec 2025
Pfizer reported an ATTR sales decline in the US. Should newer market entrants Alnylam and BridgeBio worry? - Fierce Pharma
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|